Treatments Against RA and Effect on FDG-PET/CT
Summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Daniel Solomon
Brigham and Women's Hospital
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
31 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- University of Alabama at Birmingham
Birmingham, Alabama, United States
- Loma Linda University Clinical Trial Center
Loma Linda, California, United States
- David Geffen School of Medicine at Ucla
Los Angeles, California, United States
- Brigid Freyne, Md Inc.
Murrieta, California, United States
- Desert Medical Advances
Palm Desert, California, United States
- University of California San Francisco
San Francisco, California, United States
- Nazanin Firooz Md, Inc.
West Hills, California, United States
- Robert W. Levin, Md, Pa
Clearwater, Florida, United States
- Iris Research and Development
Plantation, Florida, United States
- Southwest Florida Clinical Research Center
Tampa, Florida, United States
- University of Kentucky
Lexington, Kentucky, United States
- the Center for Rheumatology and Bone Research
Wheaton, Maryland, United States
- Brigham and Women'S Hospital
Boston, Massachusetts, United States
- Massachusetts General Hospital
Boston, Massachusetts, United States
- University of Michigan
Ann Arbor, Michigan, United States
- Washington University Medical Center
St Louis, Missouri, United States
- Dartmouth-Hitchcock Medical Center
Lebanon, New Hampshire, United States
- Northwell Health
Great Neck, New York, United States
- Columbia University Medical Center
New York, New York, United States
- Mount Sinai- Icahn School of Medicine
New York, New York, United States
- New York University School of Medicine
New York, New York, United States
- University of North Carolina at Chapel Hill
Chapel Hill, North Carolina, United States
- Cleveland Clinic
Cleveland, Ohio, United States
- Oregon Health & Science University
Portland, Oregon, United States
- Altoona Research Center
Duncansville, Pennsylvania, United States
- University of Pennsylvania
Philadelphia, Pennsylvania, United States
- University of Pittsburgh Medical Center
Pittsburgh, Pennsylvania, United States
- Metroplex Clinical Research Center
Dallas, Texas, United States
- University of Texas Health Science Center at Houston
Houston, Texas, United States
- Baylor Scott & White Medical Center- Temple
Temple, Texas, United States
- Seattle Rheumatology Associates
Seattle, Washington, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 31 Jul 2016
- Primary completion
- 31 May 2021
- Completion
- 31 May 2021
- Last update posted
- 26 Oct 2022
- Registered enrollment
- 159
- Registry id
- NCT02374021
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.